

DAFTAR PUSTAKA

1. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA [Internet]. 2020 Feb 11 [cited 2022 Dec 7];323(6):548–60. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2760741>
2. Baumann CR. Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism Relat Disord [Internet]. 2012 [cited 2022 Dec 7];18 Suppl 1(SUPPL. 1). Available from: <https://pubmed.ncbi.nlm.nih.gov/22166466/>
3. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord [Internet]. 2014 Nov 1 [cited 2022 Dec 7];29(13):1583–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/24976103/>
4. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet (London, England) [Internet]. 2021 Jun 12 [cited 2022 Dec 7];397(10291):2284–303. Available from: <https://pubmed.ncbi.nlm.nih.gov/33848468/>
5. Dan P, Gunawan G, Dalhar M, Kurniawan SN. PARKINSON AND STEM CELL THERAPY. MNJ (Malang Neurol Journal) [Internet]. 2017 Jan 1 [cited 2022 Dec 7];3(1):39–46. Available from: <https://mnj.ub.ac.id/index.php/mnj/article/view/250>
6. Rodnitzky RL. Visual dysfunction in Parkinson's disease. Clin Neurosci. 1998;5(2):102–6.
7. Moreno-Ramos T, Benito-León J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. J Alzheimers Dis [Internet]. 2013 [cited 2022 Dec 7];34(3):659–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/23271313/>
8. Bohnen NI, Albin RL, Müller MLTM, Petrou M, Kotagal V, Koeppe RA, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol [Internet]. 2015 Feb 1 [cited 2022 Dec 7];72(2):194–200. Available from: <https://pubmed.ncbi.nlm.nih.gov/25506674/>
9. Chang Z, Xie F, Li H, Yuan F, Zeng L, Shi L, et al. Retinal Nerve Fiber Layer Thickness and Associations With Cognitive Impairment in Parkinson's Disease. Front Aging Neurosci. 2022 Feb 10;14:85.
10. Kerker JS, Waheed NK, Goldman DR. Handbook of retinal OCT: optical coherence tomography.
11. Bayram D, Yüksel G, Bayram T, Türeli H. Optical coherence tomography findings in Parkinson's and Alzheimer's disease -retinal changes in neurodegenerative disease. Noropsikiyatri Ars. 2021;58(2):103–7.



12. DeMaagd G, Philip A. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. *P T*. 2015 Aug;40(8):504–32.
13. Ehgoetz Martens KA, Shine JM, Walton CC, Georgiades MJ, Gilat M, Hall JM, et al. Evidence for subtypes of freezing of gait in Parkinson's disease. *Mov Disord* [Internet]. 2018 Jul 1 [cited 2022 Dec 7];33(7):1174–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/30153383/>
14. Chung SJ, Yoo HS, Lee HS, Oh JS, Kim JS, Sohn YH, et al. The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease. *Clin Nucl Med* [Internet]. 2018 Nov 1 [cited 2022 Dec 7];43(11):787–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/30153150/>
15. Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. *Parkinsonism Relat Disord* [Internet]. 2016 Jan 1 [cited 2022 Dec 7];22:48–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/26585090/>
16. Rajsombath MM, Nam AY, Ericsson M, Nuber S. Female Sex and Brain-Selective Estrogen Benefit α -Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice. *J Neurosci* [Internet]. 2019 Sep 18 [cited 2022 Dec 7];39(38):7628–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/31405930/>
17. Yu Z, Zhang S, Wang D, Fan M, Gao F, Sun W, et al. The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review. *Medicine (Baltimore)* [Internet]. 2017 Nov 1 [cited 2022 Dec 7];96(45). Available from: [/pmc/articles/PMC5690738/](https://pubmed.ncbi.nlm.nih.gov/30153383/)
18. Kouli A, Torsney KM, Kuan WL. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. *Park Dis Pathog Clin Asp* [Internet]. 2018 Dec 22 [cited 2022 Dec 7];3–26. Available from: <https://pubmed.ncbi.nlm.nih.gov/30702842/>
19. Breckenridge CB, Berry C, Chang ET, Sielken RL, Mandel JS. Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. *PLoS One* [Internet]. 2016 Apr 1 [cited 2022 Dec 8];11(4). Available from: <https://pubmed.ncbi.nlm.nih.gov/27055126/>
20. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann Neurol* [Internet]. 2012 Dec [cited 2022 Dec 7];72(6):893–901. Available from: <https://pubmed.ncbi.nlm.nih.gov/23071076/>
21. Gasser T, Gasser T. Genetic basis of Parkinson's disease: inheritance,



penetrance, and expression. *Appl Clin Genet* [Internet]. 2011 May 31 [cited 2022 Dec 7];4:67–80. Available from: <https://pubmed.ncbi.nlm.nih.gov/23776368/>

22. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet* 2009 4112 [Internet]. 2009 Nov 15 [cited 2022 Dec 7];41(12):1308–12. Available from: <https://www.nature.com/articles/ng.487>
23. Perkin GD, David GDG. *An Atlas of PARKINSON ' S DISEASE AND RELATED DISORDERS* Foreword by Library of Congress Cataloging-in-Publication Data. 2004;
24. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res* [Internet]. 2004 Oct [cited 2022 Dec 7];318(1):121–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/15338272/>
25. Brust JCM (John CM. Current diagnosis & treatment in neurology. 2012 [cited 2022 Dec 7];573. Available from: https://books.google.com/books/about/CURRENT_Diagnosis_Treatment_Neurology_Se.html?hl=id&id=YSTyQNcQtxEC
26. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol* [Internet]. 2013 Jan [cited 2022 Dec 7];20(1):16–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/23279440/>
27. Jankovic J. Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry* [Internet]. 2008 [cited 2022 Dec 7];79(4):368–76. Available from: <https://pubmed.ncbi.nlm.nih.gov/18344392/>
28. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. *Neurodegener Dis* [Internet]. 2010 Jul [cited 2022 Dec 7];7(5):284–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/20616563/>
29. Castilla-Cortázar I, Aguirre GA, Femat-Roldán G, Martín-Estal I, Espinosa L. Is insulin-like growth factor-1 involved in Parkinson's disease development? *J Transl Med* [Internet]. 2020 Feb 11 [cited 2022 Dec 7];18(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/32046737/>
30. Samuels MA, Ropper AH. Samuels's [sic] Manual of neurologic therapeutics. 2010;607.
31. Armstrong RA. Oculo-Visual Dysfunction in Parkinson's Disease. *J Parkinsons Dis* [Internet]. 2015 Nov 21 [cited 2022 Dec 7];5(4):715–26. Available from: <https://pubmed.ncbi.nlm.nih.gov/26599301/>



uyen-Legros J, Harnois C, Paolo T, Simon A. The retinal dopamine system Parkinson's disease. undefined. 1993;

33. Müller MLTM, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. *Curr Neurol Neurosci Rep* [Internet]. 2013 Sep 1 [cited 2022 Dec 7];13(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/23943367/>
34. Kamata Y, Hara N, Satou T, Niida T, Mukuno K. Investigation of the pathophysiology of the retina and choroid in Parkinson's disease by optical coherence tomography. *Int Ophthalmol* [Internet]. 2022 May 1 [cited 2022 Dec 7];42(5):1437. Available from: </pmc/articles/PMC9122847/>
35. Lee JY, Martin-Bastida A, Murueta-Goyena A, Gabilondo I, Cuenca N, Piccini P, et al. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. *Nat Rev Neurol* 2022 184 [Internet]. 2022 Feb 17 [cited 2022 Dec 7];18(4):203–20. Available from: <https://www.nature.com/articles/s41582-022-00618-9>
36. Sengupta P, Dutta K, Ghosh S, Mukherjee A, Pal S, Basu D. Optical coherence tomography findings in patients of parkinson's disease: An Indian perspective. *Ann Indian Acad Neurol* [Internet]. 2018 Apr 1 [cited 2022 Dec 7];21(2):150. Available from: <https://www.annalsofian.org/article.asp?issn=0972-2327;year=2018;volume=21;issue=2;spage=150;epage=155;aulast=Sengupta>
37. Lumbroso B, Rispoli M (Ophthalmologist), Savastano MC. Practical handbook of OCT: (retina, choroid, glaucoma). [cited 2022 Dec 8];188. Available from: <https://www.ebay.com/p/12046549028>
38. Garcia-Martin E, Rodriguez-Mena D, Satue M, Almarcegui C, Dolz I, Alarcia R, et al. Electrophysiology and Optical Coherence Tomography to Evaluate Parkinson Disease Severity. *Invest Ophthalmol Vis Sci* [Internet]. 2014 Feb 1 [cited 2022 Dec 8];55(2):696–705. Available from: www.iovs.org
39. Reuser M, Bonneux L, Willekens F. The effect of risk faktors on the duration of cognitive impairment: A multistate life table analysis of the U.S. Health and Retirement Survey. 2010.
40. Jeffry S, Nevid, Spencer A, Rathus, Beverly G. Psikologi abnormal. Erlangga ; Jakarta. 2005.
41. Panentu D, Irfan M. Uji validitas dan reliabilitas butir pemeriksaan dengan montreal cognitive assesment versi Indonesia (MOCA-Ina) Pada Insan Pasca Stroke Fase Recovery. *Jurnal fisioterapi*; 2013. 13(1): 55-67.
42. Alfindra T. Hubungan antara gangguan kognitif dengan retinopati hipertensi pada penderita pasca stroke iskemik. Universitas Diponegoro; 2011.



en Y. The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. Shanghai University. 2013.